Search

Search Constraints

You searched for: Author/Creator Ali, Shazia

Search Results

1. 1079. Casirivimab and Imdevimab (CAS + IMD) Antibody Combination for the Treatment of Immunocomprised Hospitalized Patients with COVID-19. (15th December 2022)

2. A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects. (December 2020)

3. Effect of time duration of digestion/decontamination technique on yield of mycobacteria and contamination rates from sterile body fluids (pleural and ascitic fluid) and pus specimens. (December 2016)

4. Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial. Issue 10 (October 2022)

7. LB4. Casirivimab and Imdevimab for Treatment of Hospitalized Patients With COVID-19 Receiving Low Flow or No Supplemental Oxygen. (4th December 2021)

10. Toward e‐Scales: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales. Issue 2 (28th December 2020)